Last reviewed · How we verify
R-CHOP/R-DHAP
R-CHOP/R-DHAP is a combination chemotherapy regimen that uses rituximab (anti-CD20 monoclonal antibody) plus alternating cycles of CHOP and DHAP chemotherapy to kill lymphoma cells.
R-CHOP/R-DHAP is a combination chemotherapy regimen that uses rituximab (anti-CD20 monoclonal antibody) plus alternating cycles of CHOP and DHAP chemotherapy to kill lymphoma cells. Used for Relapsed or refractory diffuse large B-cell lymphoma (DLBCL), Mantle cell lymphoma.
At a glance
| Generic name | R-CHOP/R-DHAP |
|---|---|
| Also known as | rituximab, CHOP, DHAP |
| Sponsor | Prof. Dr. M. Dreyling (co-chairman) |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 (rituximab component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets CD20 antigen on B-cell lymphomas, enabling antibody-dependent cellular cytotoxicity and direct apoptosis. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and DHAP (dexamethasone, high-dose cytarabine, cisplatin) are cytotoxic chemotherapy regimens that damage DNA and disrupt cell division. The alternating schedule aims to overcome chemotherapy resistance in aggressive lymphomas.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Nausea/vomiting
- Infusion reactions (rituximab)
- Cardiotoxicity (doxorubicin)
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma (PHASE2)
- A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients (PHASE2)
- Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years
- ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma (PHASE3)
- Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL (PHASE3)
- A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-CHOP/R-DHAP CI brief — competitive landscape report
- R-CHOP/R-DHAP updates RSS · CI watch RSS
- Prof. Dr. M. Dreyling (co-chairman) portfolio CI